AFM-24I is a monoclonal antibody commercialized by Affimed, with a leading Phase II program in Solid Tumor. According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of AFM-24I’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for AFM-24I is expected to reach an annual total of $321 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
AFM-24I Overview
AFM-24I is under development for the treatment of solid tumors including but not limited to colorectal cancer, head and neck cancer squamous cell carcinoma, lung cancer, gastroesophageal (GE) junction carcinomas, biliary tract cancer, metastatic hepatocellular carcinoma and metastatic colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, cervical cancer, urothelial cancer, renal cell carcinoma, and glioblastoma multiforme. The drug candidate is a bi-specific monoclonal antibody act by targeting NK-cell via its CD16A receptor and tumor-specific wild type epidermal growth factor receptor (EGFR). FM-24 is a bi-specific, tetravalent human antibody. The drug candidate is developed based on Redirected Optimized Cell Killing (ROCK) platform. It is administered through intravenous route.
Affimed Overview
Affimed, is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. It develops pipeline products for the treatment of cancers. The pipleline products includes AFM24-203+ Adoptive NK Cells, AFM13-104+Adoptive NK Cells to treat certain CD30-positive (CD30+) cancers. AFM24-101 Monotherapy, AFM24-102+ANTI-PD-L1, AFM24-103 and Adoptive NK Cells, AFVT-2101 (AFM32) targets solid tumors. AFM28-101 Monotherapy, AFM28 + Adoptive NK Cells is for the treatment of acute myeloid leukemia (AML). AFM13-103 + Anti-PD-1 treats hodgkin lymphoma. AFM13-202 Monotherapy treats peripheral T cell lymphoma. Affimed is headquartered in Heidelberg, Baden-Wurttemberg, Germany.
The company reported revenues of (Euro) EUR8.3 million for the fiscal year ended December 2023 (FY2023), a decrease of 80% over FY2022. The operating loss of the company was EUR106.7 million in FY2023, compared to an operating loss of EUR88.1 million in FY2022. The net loss of the company was EUR105.9 million in FY2023, compared to a net loss of EUR86 million in FY2022.
The company reported revenues of EUR0.2 million for the first quarter ended March 2024, a decrease of 62.5% over the previous quarter.
For a complete picture of AFM-24I’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.